Asia PacificENPublic drug registration overview
South Korea Pharmaceutical Registration Pathway
Market Overview Market profile: South Korea has a mature pharmaceutical regulatory system with defined pathways for innovative drugs, biosimilars, and generics. Korean materials an...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.
AI Citation Summary
- Country: South Korea Pharmaceutical Registration Pathway
- Product line: Pharmaceuticals
- Regulator / source: Market profile: South Korea has a mature pharmaceutical regulatory system with defined pathways for innovative drugs, biosimilars, and generics. Korean materials and local MAH/importer structure are critical.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulators typically question safety, efficacy, quality, GMP, BE/clinical evidence, labeling, and risk management. Project plans should reserve at least one deficiency-response cycle and should not treat official target timelines as guaranteed launch dates.
- Key fees: Marketing authorisation for medicines in South Korea is generally managed by Ministry of Food and Drug Safety (MFDS). For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through https://www.mfds.go.kr/eng before project launch for current forms, systems, fees, and guidance.
- Local requirement: Market profile: South Korea has a mature pharmaceutical regulatory system with defined pathways for innovative drugs, biosimilars, and generics. Korean materials and local MAH/importer structure are critical.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
South Korea Pharmaceutical Registration Pathway
Market Overview
- Market profile: South Korea has a mature pharmaceutical regulatory system with defined pathways for innovative drugs, biosimilars, and generics. Korean materials and local MAH/importer structure are critical.
- Regulatory maturity: High. MFDS regulates drug approval, clinical trials, GMP, pharmacovigilance, and post-approval changes.
- Core decision: Classify the product as new drug, data-submission drug, generic, biologic, or imported drug and plan local clinical/bridging needs.
Regulator
- Authority: Ministry of Food and Drug Safety (MFDS)
- Official portal: https://www.mfds.go.kr/eng
Registration Pathway
During the limited-time free period, sign in or register to view the complete pharmaceutical country report.